CHAPTER 1 - MARKET SUMMARY
Market Overview
The Vietnam Pharmaceutical Market operates through imported originator drugs, domestic generics, OTC medicines, traditional products, and hospital procurement flows. Demand is structurally anchored by broad insurance coverage, with 94.2% of the population covered in 2024 . This shifts prescription volumes toward reimbursed channels while preserving cash-pay demand in pharmacies, making formulary inclusion and retail availability decisive commercial variables.
Southern Vietnam is the dominant commercial hub because Ho Chi Minh City concentrates specialist hospitals, distributor warehouses, retail pharmacy chains, and multinational sales teams. Nationwide supply is supported by more than 40,500 pharmacies, 54,000 drug counters, and nearly 800 medicine cabinets in 2025 . This density lowers last-mile access friction, but also intensifies channel margin competition.
Market Value
USD 8.58 Bn
2025
Dominant Region
Southern Vietnam
Dominant Segment
Generic Drugs
fastest growing
Total Number of Players
250+
Future Outlook
The Vietnam Pharmaceutical Market is expected to move from USD 8.58 Bn in 2025 to USD 13.41 Bn in 2031 , implying a forecast CAGR of 7.7% . The forecast path remains below the most aggressive secondary estimates because the model discounts reimbursement pressure, tender pricing, and imported specialty drug affordability. The 2027 market marker is USD 9.96 Bn , reflecting continued expansion in generics, prescription chronic care, and high-value hospital therapies. The historical market expanded at 8.0% CAGR from 2020 to 2025 , supported by retail access, import recovery, and insurance coverage.
Strategic growth will be led by local production upgrading, bioequivalence requirements, oncology and cardiovascular demand, and the shift from fragmented pharmacy counters to controlled chain retail. Forecast value growth exceeds volume growth because mix shifts toward specialty medicines, biosimilars, and higher-standard generics. Domestic production currently meets only part of value demand, leaving imported originators and premium therapies structurally important through 2031. However, policy targets for 2030 create a measurable localization runway, especially for contract manufacturing, EU-GMP plants, and technology transfer partnerships. Margin winners will combine registration speed, tender access, and differentiated channel coverage.
7.7%
Forecast CAGR
$13,410 Mn
2030 Projection
Base Year
2025
Historical Period
2020-2025
Forecast Period
2026-2031
Historical CAGR
8.0%
CHAPTER 2 - SCOPE OF REPORT
Scope of the Market
CHAPTER 3 - Key Stakeholders
Key Target Audience
Key stakeholders who can leverage from this market analysis for investment, strategy, and operational planning.
Investors
CAGR, localization, specialty mix, tender risk
Corporates
portfolio access, registration timing, channel margins
Government
drug security, GMP upgrading, import substitution
Operators
distribution reach, quality systems, cold chain
Financial institutions
working capital, FX exposure, capex bankability
CHAPTER 4 - Market Size & Growth
Market Size, Growth Forecast and Trends
This section evaluates the historical market size, analyzes year-over-year growth dynamics, and presents forecast projections supported by market performance indicators and demand-side drivers.
Historical and Projected Market Size (USD Mn)
YoY Growth Rate (%)
Market Value vs Volume Growth (%)
Historical Market Performance (2020-2025)
Historical performance shows a stable expansion cycle rather than a one-off pandemic distortion. The market trough occurred in 2020 at USD 5.84 Bn , while the 2025 base reached USD 8.58 Bn . Growth accelerated through reimbursement normalization and retail refill behavior, while the strongest operational inflection was import recovery in 2024, when eight-month pharmaceutical imports rose 25.2% . Demand concentration remained strongest in urban hospital and pharmacy networks, but rural coverage improved through commune medicine cabinets and district-level dispensing points.
Forecast Market Outlook (2026-2031)
The forecast path implies a value CAGR of 7.7% , with a 2027 interim market of USD 9.96 Bn and a 2031 terminal market of USD 13.41 Bn . Growth remains value-accretive because the product mix shifts toward chronic disease therapy, oncology, biosimilars, and higher-standard domestically made generics. Volume growth is projected to remain near 6.4% to 6.6% , below value growth, indicating price and mix uplift. Local manufacturing gains should reduce import intensity gradually, but premium patented drugs keep imports structurally material.
CHAPTER 5 - Market Data
Market Breakdown
The Vietnam Pharmaceutical Market is moving from high-volume generic consumption toward a more regulated, mixed market of imported specialty products, domestic EU-GMP generics, and retail chronic-care dispensing. The table below locks market value, import intensity, domestic value participation, and retail access metrics across historical and forecast years.
Year | Market Size (USD Mn) | YoY Growth (%) | Pharmaceutical Imports (USD Bn) | Domestic Value Share (%) | Retail Dispensing Points (000) | Period |
|---|---|---|---|---|---|---|
| 2020 | $5,840 Mn | +- | 3.20 | 42.0% | Forecast | |
| 2021 | $6,307 Mn | +8.0% | 3.25 | 43.0% | Forecast | |
| 2022 | $6,812 Mn | +8.0% | 3.45 | 44.0% | Forecast | |
| 2023 | $7,357 Mn | +8.0% | 3.73 | 45.0% | Forecast | |
| 2024 | $7,940 Mn | +7.9% | 4.40 | 46.0% | Forecast | |
| 2025 | $8,580 Mn | +8.1% | 4.30 | 46.5% | Forecast | |
| 2026F | $9,250 Mn | +7.8% | 4.45 | 47.8% | Forecast | |
| 2027F | $9,960 Mn | +7.7% | 4.60 | 49.0% | Forecast | |
| 2028F | $10,730 Mn | +7.7% | 4.76 | 50.0% | Forecast | |
| 2029F | $11,560 Mn | +7.7% | 4.93 | 51.0% | Forecast | |
| 2030F | $12,450 Mn | +7.7% | 5.10 | 52.0% | Forecast | |
| 2031F | $13,410 Mn | +7.7% | 5.28 | 53.0% | Forecast |
Pharmaceutical Imports
USD 2.75 Bn, first eight months of 2024, Vietnam . Import exposure signals premium therapy dependence and foreign currency risk. France, the US, Germany, and India were the leading import origins, shaping procurement strategy and distributor working capital.
Domestic Value Share
46% of drug demand value, 2025, Vietnam . This gap creates a localization thesis for EU-GMP generics, biosimilars, and contract manufacturing. The 2030 policy target lifts domestic value participation to a strategic procurement criterion.
Retail Dispensing Points
95.3 thousand points, 2025, Vietnam . The network includes pharmacies, drug counters, and commune medicine cabinets. Scale supports access, but fragmentation dilutes pricing control unless manufacturers build stronger chain and wholesaler partnerships.
CHAPTER 6 - Segmentation
Market Segmentation Framework
Comprehensive analysis across key dimensions providing insights into market structure, consumer preferences, and distribution patterns.
No of Segments
7
Dominant Segment
Product Type
Fastest Growing Segment
Therapeutic Area
Product Type
Therapeutic Area
Care Setting
Customer Type
Distribution Channel
Technology
Geography
Key Segmentation Takeaways
Comprehensive analysis across all extracted segmentation dimensions providing insights into market structure, consumer preferences, and distribution patterns.
Product Type
Product mix is the most commercially dominant segmentation dimension because importers, domestic manufacturers, and pharmacies allocate capital around molecule complexity, regulatory pathway, and channel economics. Small molecule generics retain high volume relevance, while biologics and biosimilars drive a higher value pool due to chronic disease, oncology, and hospital formulary demand.
Therapeutic Area
Therapeutic area is the fastest growing dimension because oncology, diabetes, cardiovascular, respiratory, and immune-mediated diseases are reshaping prescriptions. Oncology and specialty care are the highest-growth Level-2 sub-segment, supported by hospital upgrading, imported treatment protocols, and payer willingness for clinically differentiated therapies.
CHAPTER 7 - Regional Analysis
Regional Analysis
Vietnam ranks as a mid-to-large ASEAN pharmaceutical market, below Indonesia, Thailand, and the Philippines by 2025 value, but ahead of Malaysia by scale and manufacturing momentum. Its structural advantage is the combination of policy-led localization, broad health insurance coverage, and a dense retail dispensing network.
Focus Country Ranking
4th
Focus Country Market Size
USD 8.58 Bn
Vietnam CAGR (2026-2031)
7.7%
Focus Country Ranking
4th
Focus Country Market Size
USD 8.58 Bn
Vietnam CAGR (2026-2031)
7.7%
Regional Analysis (Current Year)
Market Position
Vietnam ranks 4th among five peer markets , with USD 8.58 Bn in 2025 , supported by insurance coverage and dense retail access.
Growth Advantage
Vietnam’s 7.7% forecast CAGR is broadly in line with Thailand and the Philippines, but stronger than Malaysia, positioning it as a localization-led challenger.
Competitive Strengths
Vietnam combines 243 GMP-WHO plants , 29 higher-standard plants , and 2030 localization targets, improving the case for technology transfer and contract manufacturing.
CHAPTER 8 - INDUSTRY ANALYSIS
Growth Drivers, Market Challenges & Market Opportunities
Comprehensive analysis of key factors shaping the Vietnam Pharmaceutical Market, including growth catalysts, operational challenges, and emerging opportunities across production, distribution, and consumer segments.
Growth Drivers
Universal Coverage and Chronic Care Demand
2024, Vietnam
- 89.55 million insured healthcare service users (H1 2024, Vietnam) create recurring prescription demand and strengthen hospital-pharmacy throughput.
- USD 2.62 Bn insurance benefit payments (H1 2024, Vietnam) support formal medicine consumption and reduce cash-flow volatility for reimbursed suppliers.
- 9.4% adult segment CAGR (forecast period, Vietnam) favors chronic-disease portfolios, especially cardiovascular, metabolic, and respiratory therapies.
Localization and Manufacturing Upgrade
2025, Vietnam
- 29 EU-GMP or PIC/S-level plants (2025, Vietnam) improve eligibility for premium tenders and export-oriented manufacturing partnerships.
- 70% domestic value target (2030, Vietnam) shifts procurement incentives toward local production and creates a measurable investment hurdle for import-led models.
- 100 original drugs and biologics technology transfer target (2030, Vietnam) supports licensing, CMO partnerships, and specialty manufacturing economics.
Retail Network Density and Access
2025, Vietnam
- 40,500 pharmacies (2025, Vietnam) create a large retail route-to-market for branded generics and self-medication categories.
- 54,000 drug counters (2025, Vietnam) extend semi-urban reach and enable manufacturers to monetize lower-pack-size formats.
- Nearly 800 commune medicine cabinets (2025, Vietnam) improve rural continuity of supply and strengthen essential medicine availability.
Market Challenges
High Import Dependence in Value Terms
2024, Vietnam
- 13.3% import origin share from France (8M 2024, Vietnam) reflects concentration in premium supply and foreign exchange exposure.
- 46% domestic value coverage (2025, Vietnam) leaves high-value medicines dependent on import registration and foreign manufacturers.
- 20% raw material production target (2030, Vietnam) shows API self-sufficiency remains limited, pressuring margins when input prices move.
Quality Upgrade Costs
2030, Vietnam
- 29 higher-standard plants out of 243 (2025, Vietnam) show the upgrade gap for sterile, biosimilar, and export-grade production.
- 100% GLP testing target (2030, Vietnam) raises compliance investment needs across quality control and batch release capacity.
- 30% bioequivalence-linked generic target (2030, Vietnam) may pressure low-cost manufacturers without BA/BE access or dossier capability.
Fragmented Channel Economics
2025, Vietnam
- 54,000 drug counters (2025, Vietnam) complicate trade promotion control, outlet education, and compliance monitoring for branded medicines.
- 100% drug safety monitoring target (2030, Vietnam) raises pharmacovigilance burden for products distributed across fragmented retail.
- 100% interconnection target for retail and wholesale facilities (2030, Vietnam) requires digital compliance across thousands of outlets.
Market Opportunities
EU-GMP Generic Manufacturing
2025, Vietnam
- USD 13.41 Bn market by 2031 (Vietnam) supports investment in differentiated generics with stronger quality positioning and tender access.
- 70% domestic value target (2030, Vietnam) benefits investors backing local formulation, sterile lines, and dossier-compliant manufacturing.
- 30% bioequivalence-linked generic target (2030, Vietnam) requires BA/BE capability and raises barriers against low-quality commoditized products.
Specialty and Biosimilar Partnerships
2030, Vietnam
- 40.2% biologics and biosimilars share (2024, Vietnam) indicates value concentration in complex therapies and creates partner-selection upside.
- 11.3% oncology CAGR (forecast period, Vietnam) benefits hospital-focused importers, specialty distributors, and clinical trial platforms.
- 100% clinical pharmacy implementation target (2030, Vietnam) supports safer specialty use and strengthens hospital-level adoption readiness.
Digital Pharmacy and Traceability
2030, Vietnam
- 100% interconnection target for production, wholesale, import/export, and retail (2030, Vietnam) enables real-time inventory and origin tracking.
- 95.3 thousand dispensing points (2025, Vietnam) create a large addressable base for pharmacy ERP, compliance, and ordering tools.
- 100% level-4 online public service integration target (2030, Vietnam) requires regulated workflows for registrations, renewals, and post-market updates.
CHAPTER 9 - Competitive Landscape
Competitive Landscape Overview
The market is fragmented, import-influenced, and regulation-intensive, with multinational players leading high-value patented therapies while domestic manufacturers compete in generics, OTC, traditional medicines, and hospital tenders.
Market Share Distribution
Top 5 Players
Market Dynamics
8 new entrants in the past 5 years, indicating strong market attractiveness and growth potential.
Company Name | Market Share | Headquarters | Founding Year | Core Market Focus |
|---|---|---|---|---|
Sanofi Vietnam | Approx. 4.5% | Paris, France | 2004 | Prescription medicines, vaccines, diabetes, consumer health |
GlaxoSmithKline Vietnam | Approx. 3.7% | London, United Kingdom | 2000 | Respiratory, vaccines, specialty medicines |
AstraZeneca Vietnam | Approx. 3.1% | Cambridge, United Kingdom | 1999 | Oncology, cardiovascular, renal, respiratory |
Pfizer Vietnam | Approx. 2.8% | New York, United States | 1849 | Innovative prescription drugs, vaccines, anti-infectives |
Novartis Vietnam | Approx. 2.5% | Basel, Switzerland | 1996 | Innovative medicines, oncology, immunology |
Roche Vietnam | Approx. 2.1% | Basel, Switzerland | 1896 | Oncology, specialty therapies, diagnostics-linked care |
DHG Pharma | Approx. 2.0% | Can Tho, Vietnam | 1974 | Domestic generics, OTC, antibiotics, consumer healthcare |
Bayer Vietnam | Approx. 1.7% | Leverkusen, Germany | 1863 | Consumer health, cardiovascular, specialty medicines |
Traphaco | Approx. 1.2% | Hanoi, Vietnam | 1972 | Traditional medicine, OTC, branded generics |
Imexpharm | Approx. 1.0% | Dong Thap, Vietnam | 1977 | EU-GMP generics, antibiotics, hospital products |
Cross Comparison Parameters
The report provides detailed cross-comparison of key players across 10 performance parameters to identify competitive strengths and weaknesses.
EU-GMP Manufacturing Footprint
Hospital Tender Coverage
Vietnam Revenue Growth
Gross Margin Stability
Analysis Covered
Market Share Analysis:
Ranks imported brands and domestic producers by estimated value.
Cross Comparison Matrix:
Benchmarks quality systems, tenders, revenue, and margin resilience.
SWOT Analysis:
Identifies localization strengths, import risks, and specialty opportunities.
Pricing Strategy Analysis:
Compares tender, retail, reimbursed, and specialty pricing models.
Company Profiles:
Profiles market focus, footprint, and strategic relevance.
CHAPTER 10 - REPORT TOC
CHAPTER 14 - Table of Contents
Phase 1Market Assessment Phase
11
Chapters
Phase 2Go-To-Market Strategy Phase
17
Chapters
Complete Report Coverage
201+ detailed sections covering every aspect of the market
143
Assessment Sections
58
Strategy Sections
CHAPTER 11 - Our Approach
Research Methodology
Desk Research
- Drug registration and policy review
- Import flow and customs analysis
- Listed pharmaceutical filing review
- Hospital tender and retail mapping
Primary Research
- Pharmaceutical commercial directors interviewed
- Hospital procurement managers consulted
- Retail pharmacy category heads interviewed
- Regulatory affairs managers consulted
Validation and Triangulation
- 184 respondents across value chain
- Supply-side revenue triangulation checks
- Import and demand reconciliation
- Scenario-based forecast stress testing
CHAPTER 12 - FAQ
FAQs
Still have questions?
Our research team is here to help you find the right solution
CHAPTER 13 - Related Research
Explore Related Reports
Expand your market intelligence with complementary research across regions and adjacent markets.
Regional/Country ReportsRelated market analysis across key regions
Related market analysis across key regions
Adjacent ReportsRelated markets and complementary research
Related markets and complementary research
500+
Market Research Reports
50+
Countries Covered
15+
Industry Verticals